Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Person › Details

Sara Blum Sherman (DBV Technologies S.A. (Euronext Paris: DBV + Nasdaq Global Select Market: DBVT))

Blum Sherman, Sara (DBV Technologies 201709 Director Investor Relations)


Organisation Organisation DBV Technologies S.A. (Euronext Paris: DBV + Nasdaq Global Select Market: DBVT)
Products Product public relations / investor relations / marcom (services)
  Product 2 immunotherapy

DBV Technologies S.A.. (9/1/17). "Press Release: DBV Technologies to Attend Upcoming Investor Conferences". Montrouge.

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that members of its management team will present and host investor meetings at the following investor conferences in September 2017:

Charles Ruban, Chief Commercial Officer, and Susanna Mesa, SVP, Strategy, will host investor meetings at Citi’s 12th Annual Biotech Conference in Boston, MA, on Thursday, September 7, 2017.

David Schilansky, Chief Operating Officer & Deputy Chief Executive Officer, and Susanna Mesa, SVP, Strategy, will present at the Morgan Stanley 15th Annual Global Healthcare Conference in New York, NY, on Tuesday, September 12, 2017, at 11:45am ET.

A live webcast of the Morgan Stanley 15th Annual Global Healthcare Conference will be available on the Investor Relations section of the Company’s website: A replay of the presentation will also be available on DBV’s website within one hour after the event.

About DBV Technologies

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of selfadministered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website:

DBV Investor Relations Contact
Sara Blum Sherman
Director, Investor Relations
+1 212-271-0740

DBV Media Contact
Roberta Di Giorgio
Head, Corporate Communications
+1 917-612-2861

Record changed: 2018-04-09


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Sara Blum Sherman

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top